Tasmania wary of former GM sites
15 March, 2002 by Melissa TrudingerFormer GM crop field trial sites in Tasmania are under close scrutiny from the Tasmanian Department of Primary Industries, Water and Environment.
Biotech outshines in stocks review
15 March, 2002 by Tanya HollisBiotechnology emerged as the star performer in a Pricewaterhouse Coopers review of the life sciences sector.
Plant centre will allow new research
15 March, 2002 by Melissa TrudingerResearchers have welcomed the establishment of a new Plant Culture Facility (PCF) at ANU's Research School of Biological Sciences (RSBS).
Antisense reports loss in lead-up to MS trial
15 March, 2002 by Tanya HollisAustralia's newest listed biotechnology company, Antisense Therapeutics (ASX:ANP), today recorded a first-half loss of $1.6 million as it prepares for a pre-clinical study of its multiple sclerosis therapy.
Gradipore R&D, marketing push offset sales revenue increase
14 March, 2002 by Iain ScottA 75 per cent boost in sales revenues at Sydney biological separations company Gradipore was offset by continued heavy commitments in R&D and international expansion in its half-year results, released today.
Proteome-based diagnostic has crop, human applications
14 March, 2002 by Daniella GoldbergA diagnostic tool for measuring damage to wheat within three minutes has been developed by Sydney-based biotechnology company Proteome Systems, in collaboration with C-Qentec Diagnostics, a subsidiary of Aventis Crop Science Pty Ltd.
Devices celebrate AusBiotech status
14 March, 2002 by Daniella GoldbergThe newly-formed Medical Device Network has become a formal program within industry association AusBiotech.
Dairy research gets a boost
14 March, 2002 by Tanya HollisAustralia's dairy industry will milk the rewards from a cash injection of almost $1.3 million from the Geoffrey Gardiner Dairy Foundation.
Ambri appointments to boost defence contracts
13 March, 2002 by Daniella GoldbergAustralian biotechnology company Ambri Ltd has appointed two executives to encourage new backing for the company's biological weapons detection contracts.
GTG confident of end of year profit
13 March, 2002 by Tanya HollisGenetic Technologies (ASX: GTG) is expecting to finish the year in the black despite posting an interim profit loss yesterday.
'Confident' Progen boosted by manufacturing gains
13 March, 2002 by Pete YoungHalf-year results for drug developer Progen Industries show the company enjoyed healthy revenue gains from its contract manufacturing arm while R&D spend rose slightly.
Bionomics heads north again for new partnership
13 March, 2002 by Pete YoungAustralia's first publicly-listed pure genomics research company, Bionomics Ltd, has interested a second northern hemisphere partner in its portfolio of patented genes.
Queensland's modest benefactor strikes again
11 March, 2002 by Pete YoungThe golden reach of a US philanthropist has touched the Queensland Institute of Medical Research again.
Xenome seals deal with big European
08 March, 2002 by Pete YoungFresh from inking pacts with two drug development companies, marine toxin specialist Xenome Ltd is on the verge of finalising many more similar deals, says CEO Tony Evans.
New DNA technology could spell precise GMO detection
07 March, 2002 by Daniella GoldbergAt a time when the precise detection of GMOs in food products has been an issue for the Federal government's analytical laboratories, Sydney company BTF Decisive Microbiology has launched bioparticle dispensing technology that it claimed would provide precision in quantitative DNA analysis.
